BEX1 and ovarian carcinoma: Subsequently, we discerned an amplified synergistic outcome when Brain Expressed X-linked protein 1 (BEX1) was subject to overexpression in ovarian carcinoma cellular cultures in conjunction with erlotinib administration (Figure 2C).